# A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

Source: https://onco.cc/trials/nct06914128/  
OnCo record `nct06914128` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BAY 3713372 in advanced solid tumours, run by Bayer, now recruiting.

## Summary

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors is a phase 1/2 interventional study registered as NCT06914128 by Bayer, with 450 participants planned, started 2025-03-21 and due to reach its primary completion in 2029-06-18. Interventions recorded: BAY 3713372.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06914128
- Phase: 1/2
- Setting: A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.
- Sponsor: Bayer
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT06914128: https://clinicaltrials.gov/study/NCT06914128

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Bayer](https://onco.cc/companies/bayer/)

---
JSON: https://onco.cc/api/v1/entities/nct06914128.json